WPIL Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/o7tlrsdscn3p5sb46m7sdxbb.pdf

Key Takeaways


International Business: The Growth Engine

Prakash Agarwal: "Margins are excellent and contractual periods are very good 4 years, 3 years, they get. So, I think it's completely -- it's a very big positive and learning for us, and we are very excited about how it will play out."

Domestic Business: A Tale of Two Divisions

Prakash Agarwal: "The point we're trying to highlight on the Jal Jeevan is that there is a positive news in the Jal Jeevan, which supports the outlook for the future. Similarly, South Africa, the orders, which we expected have come and it strengthens our outlook for the future. But all our businesses are performing."

Margins: In the Band, With Upside


Capital Allocation & Strategic Moves

Prakash Agarwal: "I think the points I would like to say is that we look at it as a zero-sum game. So, in the zero-sum game, the first is the Jal Jeevan was a weakness for us, which we see as a positive going forward." [18-19]

Product Business & Other Geographies


Guidance & Commitments

CommitmentSpecificsTimeline
Jal Jeevan receivable recovery~INR300 cr outstanding to start releasingStarting Q1 FY27, increasing over next couple of months
South Africa revenue rampProjects move to engineering and execution; momentum visibleFrom H2 FY27
South Africa order book executionEntire INR3,100 cr order book executed; peak revenues in year twoNext 3 to 4 years
Jal Jeevan Phase 2 tender momentumBig requirement expected; process restarted positivelyBy Q2 FY27, with large requirement by H2 FY27
O&M revenue impactFirst impact of reasonable O&M revenueFY27
International revenue share60% to 65% of consolidated revenueGoing forward
EBITDA margin range15% to 20% normalized; currently ~17%Ongoing
Acquisitions in product spaceActively exploring; hope to have resultsSoon
Tax refund on Rutschi saleAppeals filed; advisers confident of positive result~18 months (not assured)
NSE listing applicationHope to apply after raising fundsAfter fundraise

Key Metrics

MetricQ4 FY26
Consolidated revenue₹511 cr, -11% YoY
Consolidated EBITDA margin14.9%, down from 20% in Q4 FY25
Consolidated PBT₹67 cr, vs ₹65 cr in Q4 FY25
Consolidated PAT from continuing ops₹47 cr, flat YoY; PAT margin 9.11%
Standalone revenue₹201 cr, -44% YoY
Standalone EBITDA margin25.03%
Standalone net profit₹40 cr, -13% YoY; PAT margin 19.98%
Domestic product division revenue₹109 cr, vs ₹108 cr in Q4 FY25
Domestic project business revenue₹92 cr, vs ₹253 cr in Q4 FY25
Consolidated gross margin71%, down from 76% in Q4 FY25
Consolidated employee cost₹78 cr, vs ₹60 cr in Q4 FY25 on revenue of ₹572 cr
Consolidated trade receivables₹1,184 cr as of Mar '26, up from ₹820 cr in Mar '25
Total order book~₹6,000 cr as of May 2026
Product division order backlog₹579.6 cr as of Mar '26
Project order book (as per presentation)₹3,900 cr as of Mar '26
South Africa order bookZAR 400 cr as of May 2026
JJM order backlog~₹1,100 cr as of Q1 FY27
O&M order book component~₹530 cr
International revenue (FY26)₹1,136 cr, up from ₹668 cr in FY25
International EBITDA (FY26)₹152 cr, up from ₹88 cr in FY25
India EBITDA margin (FY26)21%
International EBITDA margin (FY26)13%
Consolidated product business margin (FY26)22%
Forex gain (exchange difference, FY26)₹139 cr in consolidated balance sheet
Overdue JJM receivables~₹350 cr